![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 Nicotinic Receptor Promotes Agonist-Induced Desensitization by a Protein Kinase C-Dependent MechanismDepartments of Clinical Pharmacology (H.T., S.K., K.T., S.K., T.W., I.K., T.S.) and Neuropsychiatry (M.T., T.M., M.K.), University of Toyama, Toyama, Japan; and Hokuriku National Hospital, Toyama, Japan (M.M.)
The
7 nicotinic acetylcholine receptor subunit (CHRNA7) gene harbors a high degree of polymorphism. In this study, we found a novel variant (1267 G to A) in exon 10 of the CHRNA7 gene in a Japanese population. This variant results in glycine-to-serine substitution at position 423 (G423S) located in the large cytoplasmic loop of the protein. To clarify the possibility that the G423S mutation alters the pharmacological properties of
7 receptors, acetylcholine (ACh)-elicited current through
7-G423S mutant receptors expressed in Xenopus laevis oocytes was measured using the two-electrode voltage-clamp technique. We found that the current elicited by ACh (1 mM, 5 s) through
7-G423S receptors, but not through
7 receptors, was significantly decreased by treatment with a protein kinase C activator, phorbol-12-myristate-13-acetate (PMA, 1030 nM). In addition, PMA (10 nM) selectively promoted a progressive decrease in
7-G423S current induced by repetitive application of ACh pulses (1 mM, 0.1 s, 0.170.33 Hz) compared with
7 current. PMA also enhanced the inactivation of
7-G423S mutant receptors induced by a prolonged application of choline (30 µM) without affecting
7 receptor responses. Western blot analysis showed that the treatment with PMA (30 nM) increased the serine phosphorylation level of the
7-G423S mutant receptors but not that of the wild-type receptors. These findings demonstrate that the G423S mutation promotes receptor desensitization by a protein kinase C-dependent mechanism. Thus, we provide the first evidence that a variant in the human CHRNA7 gene alters the function of
7 nicotinic receptors.
Address correspondence to: Dr. Hiroshi Tsuneki, Department of Clinical Pharmacology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. E-mail: htsuneki{at}pha.u-toyama.ac.jp